Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Ocular Cancer News

11/22/2024
BreakingCataractDry EyeLaserOcular CancerRevenue
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix
Q3-2024 Ophthalmic Revenue Roundup for Immunocore, Harrow, Tarsus, Lumibird, and Ocular Therapeutix

UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...

11/15/2024
BreakingDealsOcular Cancer
Advancium Signs Option to License Retinoblastoma Candidate from Aileron
Advancium Signs Option to License Retinoblastoma Candidate from Aileron

Aileron Therapeutics and Advancium Health Network announced Oct. 31 an exclusive option agreement for Advancium to acquire ALRN-6924, a clinical-stage oncology agent developed by Aileron prior to i...

11/14/2024
AIDiagnosticEmergingGlaucomaNewsletterOcular CancerRegulationRetinaTelehealth
Emerging Companies Pursuing Ophthalmic Indications, November 2024
Emerging Companies Pursuing Ophthalmic Indications, November 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

10/18/2024
BreakingOcular CancerRegulation
EU Grants Orphan Drug Status to Theriva’s Retinoblastoma Candidate
EU Grants Orphan Drug Status to Theriva’s Retinoblastoma Candidate

Theriva Biologics, of Rockville, Maryland, announced Oct. 16 that the European Commission had granted orphan medicinal product designation for VCN-01, its treatment candidate for retinoblastoma. VC...

10/15/2024
Clinical TrialCornealDry EyeGene TherapyGlaucomaIOLNewsletterOcular CancerRetinaSurgical
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Clinical Trial Updates for Ophthalmic Candidates, October 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

9/19/2024
Clinical TrialNewsletterOcular CancerPresbyopiaRetina
Clinical Trial Updates for Ophthalmic Candidates, September 2024
Clinical Trial Updates for Ophthalmic Candidates, September 2024

Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.

8/21/2024
BiosimilarsCornealDealsDry EyeEuropeGene TherapyGenericsIndustryLow VisionNewsletterOcular CancerPharmaPresbyopiaRegulationRetina
August 2024 Ophthalmic News Briefs
August 2024 Ophthalmic News Briefs

Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...

8/16/2024
BiosimilarsBreakingCataractDiagnosticDry EyeGlaucomaLaserOcular CancerRefractiveRetinaRevenueSurgical
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec,  Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex

AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....

8/2/2024
BreakingOcular CancerRegulation
US FDA Grants Rare Pediatric Drug Status to Theriva’s Retinoblastoma Candidate
US FDA Grants Rare Pediatric Drug Status to Theriva’s Retinoblastoma Candidate

Theriva Biologics, of Rockville, Maryland, announced July 31 that the US FDA had granted rare pediatric drug designation for VCN-01, its treatment candidate for retinoblastoma. The FDA had already ...

5/31/2024
BreakingCataractIOLOcular CancerRevenueSurgical
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore

Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...

5/22/2024
CornealDiagnosticDry EyeEmergingGene TherapyGlaucomaNewsletterOcular CancerRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Emerging Companies Pursuing Ophthalmic Indications, May 2024

Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.

5/22/2024
CornealGlaucomaMeetingNewsletterOcular CancerRetinaStudy
2024 ARVO Awards Highlight New Focus on Inflammation
2024 ARVO Awards Highlight New Focus on Inflammation

The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...

4/26/2024
BreakingCataractGlaucomaOcular CancerRetinaStudy
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research

The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...

3/8/2024
BiosimilarsBreakingIOLLaserOcular CancerRetinaRevenue
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen

UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...

11/17/2023
BreakingCataractDry EyeIOLOcular CancerPharmaRevenue
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others

UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...

10/24/2023
CataractClinical TrialDealsDiagnosticDry EyeGene TherapyGenericsIOLIndustryMicroscopesNewsletterOcular CancerRegulationRetina
October 2023 Ophthalmic News Briefs
October 2023 Ophthalmic News Briefs

Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...

10/6/2023
BreakingIndustryOcular CancerRetina
Aura Biosciences Appoints J. Jill Hopkins, MD, as Chief Medical Officer
Aura Biosciences Appoints J. Jill Hopkins, MD, as Chief Medical Officer

Aura Biosciences, of Boston, Massachusetts, announced Oct. 2 that it had appointed J. Jill Hopkins, MD, as chief medical officer and president of research and development. The company also announce...

7/25/2023
NewsletterOcular CancerRegulation
US FDA Rejects Aldeyra’s IVT Methotrexate for Primary Vitreoretinal Lymphoma
US FDA Rejects Aldeyra’s IVT Methotrexate for Primary Vitreoretinal Lymphoma

Aldeyra Therapeutics reported June 21 that the US FDA had rejected its ADX-2191 (methotrexate injection) for primary vitreoretinal lymphoma (PVRL), a rare and aggressive cancer with no FDA-approved...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more